ClinicalTrials.gov
ClinicalTrials.gov Menu

Iloprost in Preventing Lung Cancer in Former Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02237183
Recruitment Status : Recruiting
First Posted : September 11, 2014
Last Update Posted : June 13, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.

Condition or disease Intervention/treatment Phase
Cytologic Atypia Former Smoker Mild Dysplasia Drug: Iloprost Other: Laboratory Biomarker Analysis Other: Placebo Other: Quality-of-Life Assessment Other: Questionnaire Administration Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the toxicity of inhalational iloprost administered to cohorts of patients daily for 2 months, given four times a day (QID) in Cohort A followed by twice daily (BID) in Cohort B.

SECONDARY OBJECTIVES:

I. To evaluate the compliance with BID or QID dosing regimens. II. To evaluate the effect on endobronchial histology. III. To evaluate the effect on expectorated sputum cytology by both standard cytologic analysis and an automated three-dimensional morphologic analysis.

IV. To evaluate the effect on endobronchial brushing and biopsy gene expression of peroxisome proliferator-activated receptor gamma (PPARgamma), glutathione S-transferase mu (GSTmu), carboxylesterase 1 (Ces1), Fos-related antigen 1 (FosL1), cytochrome p4502e1, stearoyl coA desaturase 1, tumor necrosis factor (TNF) superfamily member 9, transforming growth factor beta (TGFbeta), Jun and a 46 gene panel associated with dysplasia persistence, using Affymetrix arrays.

V. To evaluate the improvement in chronic obstructive pulmonary disease (COPD) as measured by arterial blood gas (ABG) (improved ventilation perfusion matching), pulmonary function testing, 6-minute walk distance, quality of life (St. George's respiratory questionnaire, COPD assessment test [CAT]).

VI. To evaluate whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects.

OUTLINE: Patients are enrolled to Cohort A to completion prior to initiation of Cohort B.

COHORT A: Patients are assigned to 1 of 2 arms.

ARM I: Patients receive iloprost via inhalation using a nebulizer QID for 60 days.

ARM II: Patients receive placebo via inhalation using a nebulizer QID for 60 days.

COHORT B: Patients are assigned to 1 of 2 arms.

ARM III: Patients receive iloprost via inhalation using a nebulizer BID for 60 days.

ARM IV: Patients receive placebo via inhalation using a nebulizer BID for 60 days.

After completion of study treatment, patients are followed up at 90 days and then annually for up to 5 years.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers
Actual Study Start Date : November 5, 2015
Estimated Primary Completion Date : February 1, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Iloprost

Arm Intervention/treatment
Experimental: Arm I (iloprost QID)
Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
Drug: Iloprost
Given via inhalation
Other Names:
  • Ciloprost
  • Iloprost Clathrate
  • Ventavis
  • ZK 36374

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Placebo Comparator: Arm II (placebo QID)
Patients receive placebo via inhalation using a nebulizer QID for 60 days.
Other: Laboratory Biomarker Analysis
Correlative studies

Other: Placebo
Given via inhalation
Other Names:
  • placebo therapy
  • PLCB
  • sham therapy

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm III (iloprost BID)
Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
Drug: Iloprost
Given via inhalation
Other Names:
  • Ciloprost
  • Iloprost Clathrate
  • Ventavis
  • ZK 36374

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Placebo Comparator: Arm IV (placebo BID)
Patients receive placebo via inhalation using a nebulizer BID for 60 days.
Other: Laboratory Biomarker Analysis
Correlative studies

Other: Placebo
Given via inhalation
Other Names:
  • placebo therapy
  • PLCB
  • sham therapy

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Incidence of clinical toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 90 days ]
    Descriptive statistics (mean, standard deviation [SD], median, max, min and range) will be provided for toxicity. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.

  2. Treatment compliance, measured as the fraction of prescribed inhalations actually administered [ Time Frame: Up to 60 days ]
    Descriptive statistics (mean, SD, median, max, min and range) will be provided for compliance. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.


Secondary Outcome Measures :
  1. Response of airway histology [ Time Frame: Up to 5 years ]
    Will provide descriptive statistics for the effect on endobronchial histology, with the primary parameter being worst histology at matched sites; additional outcomes will be average histology, dysplasia index and response, as described.

  2. Serum protein profiling [ Time Frame: Up to 60 days ]
    Will provide descriptive statistics for the effect on serum proteins as quantitated by aptamer based analysis.

  3. Endobronchial brushing gene expression [ Time Frame: Up to 60 days ]
    Will provide descriptive statistics for the effect on endobronchial brushing gene expression, focusing on prostacyclin-targeted pathways.

  4. Gene expression of dysplastic lesions [ Time Frame: Up to 60 days ]
    Will provide descriptive statistics.

  5. Improvement in chronic obstructive pulmonary disease (COPD) [ Time Frame: Up to 60 days ]
    Will provide descriptive statistics for the improvement in COPD as measured by arterial blood gas (ABG) (improved ventilation perfusion matching), pulmonary function testing, 6-minute walk distance, and quality of life (St. George's respiratory questionnaire, COPD assessment test [CAT]).

  6. Whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects [ Time Frame: Up to 60 days ]
    Bronchial biopsies will be taken from an area suspicious for dysplasia and an area that appears normal. These will be cultured as described and transferred to an air liquid interface culture in which dysplasia is recapitulated. Cultures will be treated with either vehicle or iloprost and assessed for both self-renewal and differentiation to ciliated and secretory cells.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have either sputum cytologic atypia of mild dysplasia or greater or a history of bronchial biopsy with mild or greater dysplasia within the past 12 months
  • Participants must have a smoking history of 20 pack-years or greater
  • Participants must have the ability to safely undergo bronchoscopy in the judgment of the investigators
  • Participants must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Leukocytes >= 3,000/microliter
  • Platelets >= 100,000/microliter
  • Total bilirubin =< 2.0 mg/dl
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
  • Creatinine =< 2.0 mg/dl
  • Women of child-bearing potential and men having intercourse with a woman of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; Note: women are considered to be of child-bearing potential if they are not surgically sterile or are under the age of 65 and have menstruated within the last two years
  • Participants must be able to understand and willing to sign a written informed consent document

Exclusion Criteria:

  • Participants must not have used any tobacco product in the past year
  • Participants must not be currently receiving or have previously received thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment and within 12 months of entry
  • Participants must not have been treated with iloprost at any time; Note: participants on the placebo arm of previous iloprost trials are eligible, but participants on the placebo arm of cohort A of this study may not be enrolled in cohort B
  • Participants must not have used any other investigation agent within the last six months
  • Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost
  • Participants must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of investigators would jeopardize patient safety of data integrity; Note: individuals who are human immunodeficiency virus (HIV) positive will not necessarily be excluded, will be considered on a case-by-case basis, but will be required to meet criteria related to patient safety and data integrity, as assessed by investigators
  • Participants must not have a current or prior invasive malignancy within the past 6 months; participants may enroll prior to biopsy result report, unless there are findings at bronchoscopy suggesting an invasive malignancy; history of the following curatively treated cancers during any time prior to screening is allowed: non-melanoma skin cancer, cervical carcinoma in situ, and bladder carcinoma in situ
  • Participants must not have received either chemotherapy or radiotherapy within the previous 6 months; Note: participants receiving long-term adjuvant hormonal therapy (such as tamoxifen or aromatase inhibitors for breast cancer) are allowed
  • Women must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with iloprost
  • As iloprost inhibits platelet function, patients must not be taking anticoagulants, with the exception of aspirin or other non-steroidal anti-inflammatory medications
  • Participants must not have blood pressure < 95 mm Hg systolic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02237183


Locations
United States, Colorado
University of Colorado Recruiting
Denver, Colorado, United States, 80217-3364
Contact: York E. Miller    303-393-2896    york.miller@ucdenver.edu   
Principal Investigator: York E. Miller         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: York Miller Northwestern University

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02237183     History of Changes
Other Study ID Numbers: NCI-2014-01891
NCI-2014-01891 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
N01-CN-2012-00035
HHSN2612201200035I
NCI2013-02-01 ( Other Identifier: Northwestern University )
NWU2013-02-01 ( Other Identifier: DCP )
N01CN00035 ( U.S. NIH Grant/Contract )
P30CA060553 ( U.S. NIH Grant/Contract )
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: June 13, 2018
Last Verified: June 2018

Additional relevant MeSH terms:
Iloprost
Platelet Aggregation Inhibitors
Vasodilator Agents